Plocamium polyhalogenated monoterpenes are metabolites first isolated from the red algae Plocamium cartilagineum, featuring several units of unsaturation, as well as multiple halogens, including two contiguous stereogenic chlorine-bearing carbons. These molecules possess a wide range of biological activity, but most notably show cytotoxicity against a range of solid-tumor cancer cell lines. This promising activity has caught the attention of William Gerwick (Scripps Institution of Oceanography) and Dr. Fred Valeriote (Henry Ford Medical Center). The testing of several members of the Plocamium polyhalogenated monoterpene family suggests only moderate cytotoxicity levels, initial results indicate that these compounds are selective for solid tumors, while remaining nontoxic to healthy cells. However, due to the low abundance from natural sources, these compounds were only isolated in small quantities, and in vivo studies could not be conducted. The Vanderwal group at the University of California Irvine aims to develop the first synthesis of members of the Plocamium polyhalogenated monoterpenes, The proposed synthesis is concise and modular, allowing for multiple members of the class to be synthesized, as well as a host of unnatural analogues, with only minor modifications to the procedure. Initial results on the synthesis of simplified model systems are promising, and once completed, the Plocamium polyhalogenated monoterpene natural products will be synthesized. Through collaboration with Gerwick and Dr. Valeriote, the synthesized compounds will be tested for biological activity, and in the case of known bioactive members, continue in vivo studies.
The field of chemotherapeutics is always in need of drugs that are not only potent to the cancer cells, but remain nontoxic towards healthy cells. The outlined chlorinated natural products show promising activity against a range of solid tumors, as well as remaining nontoxic to other cells, but are difficult to obtain from their natural sources. The Vanderwal group has outlined a strategy to synthesize this group of compounds in order to further test their activity.
|Kasagi, Yuta; Chandramouleeswaran, Prasanna M; Whelan, Kelly A et al. (2018) The Esophageal Organoid System Reveals Functional Interplay Between Notch and Cytokines in Reactive Epithelial Changes. Cell Mol Gastroenterol Hepatol 5:333-352|
|Whelan, Kelly A; Muir, Amanda B; Nakagawa, Hiroshi (2018) Esophageal 3D Culture Systems as Modeling Tools in Esophageal Epithelial Pathobiology and Personalized Medicine. Cell Mol Gastroenterol Hepatol 5:461-478|
|Maehara, Osamu; Suda, Goki; Natsuizaka, Mitsuteru et al. (2017) Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. Carcinogenesis 38:1073-1083|
|Whelan, Kelly A; Merves, Jamie F; Giroux, Veronique et al. (2017) Autophagy mediates epithelial cytoprotection in eosinophilic oesophagitis. Gut 66:1197-1207|
|Whelan, K A; Chandramouleeswaran, P M; Tanaka, K et al. (2017) Autophagy supports generation of cells with high CD44 expression via modulation of oxidative stress and Parkin-mediated mitochondrial clearance. Oncogene 36:4843-4858|
|Natsuizaka, Mitsuteru; Whelan, Kelly A; Kagawa, Shingo et al. (2017) Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma. Nat Commun 8:1758|
|Facompre, Nicole D; Harmeyer, Kayla M; Sole, Xavier et al. (2016) JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers. Cancer Res 76:5538-49|
|Merves, Jamie F; Whelan, Kelly A; Benitez, Alain J et al. (2016) ATG7 Gene Expression as a Novel Tissue Biomarker in Eosinophilic Esophagitis. Am J Gastroenterol 111:151-3|
|Tanaka, Koji; Whelan, Kelly A; Chandramouleeswaran, Prasanna M et al. (2016) ALDH2 modulates autophagy flux to regulate acetaldehyde-mediated toxicity thresholds. Am J Cancer Res 6:781-96|
|Kagawa, S; Natsuizaka, M; Whelan, K A et al. (2015) Cellular senescence checkpoint function determines differential Notch1-dependent oncogenic and tumor-suppressor activities. Oncogene 34:2347-59|
Showing the most recent 10 out of 14 publications